Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 6/20 | 0.72 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.68 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.60 |
| ▸ | HSP90B1 | P14625 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 3/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26554271 | 0.90 | ADORA3 (0.67) | AHCYADORA3ADORA2BHSP90B1TSHR | |
| SCHEMBL26554188 | 0.87 | AHCY (0.72) | AHCYADORA3ADORA2BHSP90B1TSHR | |
| SCHEMBL24487867 | 0.84 | AHCY (0.64) | AHCYADORA3ADORA2BHSP90B1TSHR | |
| SCHEMBL20579582 | 0.84 | AHCY (1.00) | AHCYADORA3ADORA2BHSP90B1TSHR | |
| SCHEMBL10883506 | 0.82 | AHCY (0.84) | AHCYADORA3ADORA2BHSP90B1TSHR | |
| SCHEMBL26554407 | 0.81 | ACHE (0.48) | AHCYADORA3ADORA2BHSP90B1ADORA2A | |
| SCHEMBL24487771 | 0.81 | AHCY (0.82) | AHCYADORA3ADORA2BHSP90B1TSHR | |
| SCHEMBL26554248 | 0.81 | ADORA3 (0.65) | ADORA3ADORA2BADORA2AKMT2AADORA1 | |
| SCHEMBL26553722 | 0.80 | PRMT6 (0.48) | AHCYADORA3ADORA2BADORA2A | |
| SCHEMBL22393070 | 0.79 | ADORA3 (0.60) | AHCYADORA3ADORA2BHSP90B1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365970-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230332153-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365970-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | NSUN2, SNRPA, SNRPF | AHCY 3101/4885ADORA3 1358/4885ADORA2B 837/4885 |
| US-20230332153-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | NSUN2, SNRPA, SNRPF | AHCY 3101/4885ADORA3 1358/4885ADORA2B 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.